The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2741-2751

  Bergeron, Christine ^a   Ronco, Guglielmo ^b   Reuschenbach, Miriam ^c   Wentzensen, Nicolas ^d   Arbyn, Marc ^e   Stoler, Mark ^f   Von Knebel Doeberitz, Magnus ^c  

^a LABORATOIRE CERBA   (France)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

cervical cancer; cervical pathology; early detection; HPV; p16INK4a

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN;

ARTICLE; CANCER SCREENING; CARCINOGENESIS; CONTROLLED STUDY; CYTOLOGY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRUS INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX; CYTODIAGNOSIS; HOST PATHOGEN INTERACTION; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84927546211     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28900     Document Type: Article

References (74)

1. Koss LG,. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989; 261: 737-43.
2. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32.
3. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (Suppl 5): F88-F99.
4. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nature reviews. Cancer 2002; 2: 342-50.
5. Snijders PJ, Heideman DA, Meijer CJ,. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 2010; 118: 520-8.
6. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103: 368-83.
7. Wentzensen N,. Triage of HPV-positive women in cervical cancer screening. Lancet Oncol 2013; 14: 107-9.
8. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937-45.
9. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-76.
10. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 (Suppl 5): F24-F33.
11. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100: 513-7.
12. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Institute 2010; 102: 315-24.
13. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
14. von Knebel Doeberitz M, Vinokurova S,. Host factors in HPV-related carcinogenesis: cellular mechanisms controlling HPV infections. Arch Med Res 2009; 40: 435-42.
15. Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci USA 2012; 109: 10516-21.
16. zur Hausen H,. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384: 260-5.
17. Duensing S, Munger K,. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-62.
18. Thomas LK, Bermejo JL, Vinokurova S, et al. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract-A systematic review and meta-analysis. Eur J Cancer 2014; 50: 85-98.
19. Michalas SP,. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 2000; 90: 135-8.
20. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infec Dis 2007; 7: 453-9.
21. Smith JS, Melendy A, Rana RK, et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adoles Health 2008; 43: S5-S25, S25 e1-41.
22. Stanley MA,. Immunobiology of papillomavirus infections. J Reprod Immunol 2001; 52: 45-59.
23. Woodman CB, Collins SI, Young LS,. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22.
24. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (Suppl 5): F55-F70.
25. Stoler MH,. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000; 19: 16-28.
26. Doorbar J,. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-41.
27. Stoler MH, Rhodes CR, Whitbeck A, et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Human Pathol 1992; 23: 117-28.
28. Durst M, Glitz D, Schneider A, et al. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 1992; 189: 132-40.
29. Yoshida T, Sano T, Kanuma T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer 2008; 114: 83-8.
30. McLaughlin-Drubin ME, Crum CP, Munger K,. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011; 108: 2130-5.
31. Drayton S, Brookes S, Rowe J, et al. The significance of p16INK4a in cell defenses against transformation. Cell Cycle 2004; 3: 611-5.
32. Sperka T, Wang J, Rudolph KL,. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 2012; 13: 579-90.
33. Rayess H, Wang MB, Srivatsan ES,. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130: 1715-25.
34. Campisi J, d'Adda di Fagagna F,. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-40.
35. Lowe SW, Sherr CJ,. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83.
36. von Knebel Doeberitz M, Reuschenbach M, Schmidt D, et al. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012; 9: 149-63.
37. Reuschenbach M, Seiz M, von Knebel Doeberitz C, et al. Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer 2012; 130: 388-94.
38. McLaughlin-Drubin ME, Park D, Munger K,. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci USA 2013; 110: 16175-80.
39. Richart RM,. Cervical intraepithelial neoplasia. Pathol Ann 1973; 8: 301-28.
40. Darragh TM, Colgan TJ, Thomas Cox J, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynec Pathol 2013; 32: 76-115.
41. Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for hpv-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012; 136: 1266-97.
42. Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for hpv-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genital Tract Dis 2012; 16: 205-42.
43. Waxman AG, Chelmow D, Darragh TM, et al. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol 2012; 120: 1465-71.
44. Wilbur DC, Darragh TM,. Harmony at LAST. Cancer Cytopathol 2013; 121: 111-5.
45. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
46. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1389-99.
47. Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010; 133: 395-406.
48. Dijkstra MG, Heideman DA, de Roy SC, et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010; 63: 972-7.
49. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010; 34: 1077-87.
50. Zhang Q, Kuhn L, Denny LA, et al. Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 2007; 120: 351-6.
51. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treatment Rev 2009; 35: 210-20.
52. Omori M, Hashi A, Nakazawa K, et al. Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. Am J Clin Pathol 2007; 128: 208-17.
53. Hariri J, Oster A,. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007; 26: 223-8.
54. Wang JL, Zheng BY, Li XD, et al. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004; 10: 2407-14.
55. Wang SS, Trunk M, Schiffman M, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 1355-60.
56. Negri G, Bellisano G, Zannoni GF, et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008; 32: 1715-20.
57. Liao GD, Sellors JW, Sun HK, et al. p16 immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: A prospective study in China. Int J Cancer 2014; 134: 1715-24.
58. Denton KJ, Bergeron C, Klement P, et al. European CINtec Cytology Study Group. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol. 2010;(1): 12-21.
59. Roelens J, Reuschenbach M, von Knebel Doeberitz M, et al. p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol 2012; 120: 294-307.
60. Wentzensen N, Bergeron C, Cas F, et al. Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005; 105: 461-7.
61. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-66.
62. Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18: 4154-62.
63. Uijterwaal MH, Witte BI, Van Kemenade FJ, et al. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br Journal Cancer 2014; 110: 1579-86.
64. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
65. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncology 2010; 11: 249-57.
66. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncology 2012; 13: 78-88.
67. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
68. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
69. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011; 121: 505-9.
70. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137: 516-42.
71. Castle PE, Stoler MH, Wright TC, Jr,et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncology 2011; 12: 880-90.
72. Plummer M, Peto J, Franceschi S, International Collaboration of Epidemiological Studies of Cervical C,. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2012; 130: 2638-44.
73. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-7.
74. Grabe N, Lahrmann B, Pommerencke T, et al. A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. Cell Oncol 2010; 32: 109-19.